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Increased Risk of Squamous-Cell Carcinoma in
Simultaneous Pancreas Kidney Transplant Recipients
Compared with Kidney Transplant Recipients
Hermina C. Wisgerhof1, Paul J.M. van der Boog2, Johan W. de Fijter2, Ron Wolterbeek3, Geert W.
Haasnoot4, Frans H.J. Claas4, Rein Willemze1 and Jan N. Bouwes Bavinck1
The purpose of this study was to ascertain the risk of non-melanocytic skin cancer (NMSC) in simultaneous
pancreas kidney transplant recipients (SPKTRs) compared with kidney transplant recipients (KTRs) in relation to
other potential risk factors of skin cancer. In a cohort study, 208 SPKTRs were compared with 1,111 KTRs who
were transplanted during the same time period. The effects of age, sex, country of origin, time period after
transplantation, HLA matching, immunosuppressive regimen, and rejection treatments on the risk of NMSC
were investigated in multivariable Cox’s proportional hazard models. In SPKTRs, the incidence of NMSC
increased from 19 to 36%, respectively, 10 and 15 years after transplantation, which was significantly higher
compared with that in KTRs (6 and 10%, respectively). After adjustment for age and sex, SPKTRs had a 6.2
(3.0–12.8) increased risk of squamous-cell carcinoma (SCC) compared with KTRs. An additional adjustment for
maintenance immunosuppression decreased the hazard ratio to 3.1 (1.3, 7.2), which indicates partial
confounding by the immunosuppressive regimen. Adjustment for induction and rejection therapy or HLA
mismatching did not change the hazard ratio significantly. SPKTRs have an increased risk of SCC compared with
KTRs, despite partial confounding by the immunosuppressive regimen.
Journal of Investigative Dermatology (2009) 129, 2886–2894; doi:10.1038/jid.2009.181; published online 2 July 2009
INTRODUCTION
Organ-transplant recipients are at an increased risk for post-
transplant neoplasms (Hardie et al., 1980; Hartevelt et al.,
1990). Non-melanocytic skin cancers (NMSCs), especially
squamous-cell carcinomas (SCC), are the most common
malignancies and can cause substantial morbidity and even
mortality (Hartevelt et al., 1990; Bouwes Bavinck et al.,
1996; Jensen et al., 2000; Naldi et al., 2000; Euvrard et al.,
2003; Otley et al., 2005b; Moloney et al., 2006).
Increasing age, male sex, and fair complexion are the most
important host-related risk factors for skin cancer, and
exposure to sunlight, smoking, and infection with human
papillomaviruses are the most important environmental risk
factors (De Hertog et al., 2001; Bouwes Bavinck and
Feltkamp, 2004; Kasiske et al., 2004; Bouwes Bavinck
et al., 2008). Among organ-transplant recipients, immuno-
suppressive therapy forms an additional important risk factor
(Hartevelt et al., 1990; Bouwes Bavinck et al., 2007). Both
the duration and type of immunosuppression may have a
role. Azathioprine (Aza) has been reported to induce
selective UVA photosensitivity, which may result in a
cascade of reactions in the skin, ranging from the induction
of oxidative stress and mutagenic DNA lesions to the
development of skin cancer (O’Donovan et al., 2005; Cooke
et al., 2007; Montaner et al., 2007; Ulrich and Stockfleth,
2007). Cyclosporine A (CsA) can decrease DNA repair and
impair UV-induced apoptosis, which also increases the risk
of skin cancer (Yarosh et al., 2005). Poor HLA matching has
been reported to be associated with an increased risk of
NMSC (Bouwes Bavinck et al., 1991).
Among kidney-transplant recipients (KTRs) living in a
temperate climate, the prevalence of NMSC at 10 years after
transplantation varied between 10 and 27%, and at 20 years,
it varied between 40 and 60% (Hartevelt et al., 1990; Bordea
et al., 2004; Moloney et al., 2006). In Australia, the incidence
is even higher (Hardie et al., 1980; Bouwes Bavinck et al.,
1996; Ramsay et al., 2002). Heart-transplant recipients seem
to have a higher incidence of NMSC compared with KTRs,
although this may be a consequence of older age at
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transplantation in this group (Mihalov et al., 1996; Fortina
et al., 2000; Naldi et al., 2000). Less research has been
conducted in patients receiving a liver transplant. After a
follow-up period of 10 years, an incidence between 13 and
26% has been found in Dutch and Spanish liver-transplant
recipients, respectively (Haagsma et al., 2001; Herrero et al.,
2005). There are no studies that followed up lung-transplant
recipients or simultaneous pancreas kidney transplant reci-
pients (SPKTRs) for a longer period.
Since 1986, simultaneous pancreas kidney transplanta-
tions (SPKTs) are being performed in the Netherlands. At
present, more than 200 patients received an SPKT at the
Leiden University Medical Center (LUMC). The main
objective of this study was to calculate the cumulative
incidence of skin cancer in SPKTRs compared with the
incidence in KTRs who were transplanted in the same center
during the same time period.
We hypothesized that the risk of skin cancer in SPKTRs
would be higher compared with that in KTRs, because
SPKTRs are exposed to a more potent immunosuppressive
regimen and are not HLA matched in contrast to KTRs.
RESULTS
Baseline characteristics of the KTR and SPKTR
The baseline characteristics of KTRs and SPKTRs are depicted
in Table 1. The majority of the patients originated from the
Netherlands. In the KTR group, there were significantly more
patients originating from Mediterranean countries or from
countries that are associated with a darker skin type (Table 1).
Sex distribution did not differ significantly between the two
groups, but the SPKTRs were on an average 7.4 years younger
at first transplantation than were the KTRs (Po0.001). The
median follow-up time of the SPKTRs was shorter (P¼0.014),
because, during the first few years, the number of SPKTs was
still limited (Table 1). After adjustment for age, sex, and
immunosuppressive therapy, overall survival was signifi-
cantly shorter for SKPTRs compared with KTRs, with an
adjusted hazard ratio of 2.1 (1.5, 3.1).
Cumulative incidence of skin cancer in the SPKTR compared
with that in the KTR
The baseline characteristics of KTRs and SPKTRs in relation to
the development of SCC and basal-cell carcinoma (BCC) as
first events are depicted in Table 2, and potential risk factors
for NMSC, SCC, and BCC are presented for KTRs and SPKTRs
separately in Supplementary Figure S1 and Supplementary
Tables S1a and S1b. Two of the KTRs had developed an SCC
and a BCC and four only a BCC before transplantation. These
skin cancers were not considered in the analyses. None of the
SPKTRs had developed an SCC or a BCC before transplanta-
tion. The time period after transplantation was significantly
associated with the occurrence of SCC and BCC (Po0.001),
but sex was not associated with skin cancer (Table 2). In the
Cox’s proportional hazard model, increasing age at trans-
plantation was a risk factor for both types of skin cancer
(Supplementary Tables S1a and S1b).
During the follow-up period until June 2007, a total of 109
skin cancers (73 SCCs and 36 BCCs) were diagnosed in 26
(12.5%) out of 208 SPKTRs (Table 2). During the same follow-
up period, 68 (6.1%) out of 1,111 KTRs developed altogether
223 skin cancers (102 SCCs and 121 BCCs). The overall
SCC:BCC ratio in the KTR was 0.79. This ratio gradually
increased with increasing time after transplantation with
ratios of 0.67, 0.55, 0.71, and 1.0 during the first 2, 2–7, 8–12,
and 13–17 years after transplantation, respectively. The
overall SCC:BCC ratio in the SPKTR was 1.1. The ratios were
0, 1.1, and 1.4 during the periods between 2–7, 8–12, and
13–17 years after transplantation, respectively.
The cumulative incidences of NMSC, SCC, and BCC in
SPKTRs are compared with those in KTRs in Figure 1 and
Supplementary Figure S2.
Possible risk factors for skin cancer
To identify the possible factors that could explain the
increased risk of skin cancer among SPKTRs compared with
KTRs, we analyzed the influence of age, sex, country of
Table 1. Baseline characteristics of 1,111 KTRs and
208 SPKTRs
KTR SPKTR P-value
No. of patients 1111 208
Country of origin
The Netherlands 973 (87.6) 203 (97.6)
Mediterranean 58 (5.2) 3 (1.4) Po0.001
Suriname, Africa, Asia 80 (7.2) 2 (1.0)
Male: N (%) 690 (62.1) 126 (60.6) P=0.677
Age at transplant (years)
Median 48.6 40.5 Po0.001
25–75% 37.8–58.5 34.8–46.0
Follow-up (years)
Median 6.9 6.4 P=0.014
25–75% 3.6–12.1 3.5–10.1
HLA mismatches
0 178 (16.1) 1 (0.5)
1–3 774 (70.2) 52 (25.0) Po0.001
4–6 151 (13.7) 155 (74.5)
Unknown 8 0
Death: N (%) 363 (33.0) 63 (30.4) P=0.4751
Unknown 10 1
KTR, kidney transplant recipient; SPKTR, simultaneous pancreas kidney
transplant recipient.
1After adjustment for age, sex, and immunosuppressive therapy, overall
survival was significantly shorter for SKPTRs compared with KTRs with an
adjusted hazard ratio of 2.1 (1.5, 3.1).
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Table 2. Baseline characteristics according to the presence of non-melanocytic skin cancer and risk factors of skin
cancer in KTRs and SPKTRs
KTR SPKTR
Type of skin cancer
No skin cancer
(censored)
SCC as
first event
BCC as
first event P-value
No skin cancer
(censored)
SCC as
first event
BCC as
first event P-value
No. of patients: N (%) 1043 (94.0) 28 (2.5) 40 (3.6) 182 (87.5) 14 (6.7) 12 (5.8)
No. of patients with SCC 0 28 10 0 14 4
No. of patients with BCC 0 8 40 0 5 12
SCC per pat with NMSC
Mean (min–max) 0 2.5 (1–7) 0.8 (0–7) 0 4.9 (1–14) 0.3 (0–1)
BCC per pat with NMSC
Mean (min–max) 0 0.5 (0–5) 2.7 (1–20) 0 0.4 (0–2) 2.5 (1–12)
Country of origin
The Netherlands 907 (87.0) 28 (100) 38 (95.0) 177 (97.3) 14 (100) 12 (100)
Mediterranean 57 (5.5) 0 1 (2.5) Pscc=0.124 3 (1.6) 0 0 Pscc=0.821
Africa, Asia 79 (7.5) 0 1 (2.5) Pbcc=0.323 2 (1.1) 0 0 Pbcc=0.844
Male: N (%) 647 (62.0) 20 (71.4) 23 (57.5) Pscc=0.311
Pbcc=0.562
109 (59.9) 9 (64.3) 8 (66.7) Pscc=0.746
Pbcc=0.642
Age at transplant (years)
Median 48.4 51.9 49.6 Pscc=0.147 40.6 42.5 37.4 Pscc=0.933
25–75% 37.7–58.1 40.9–61.7 44.8–60.2 Pbcc=0.226 34.8–46.0 33.6–47.8 33.3–48.1 Pbcc=0.566
Follow-up (years)
Median 6.6 13.0 11.6 Pscco0.001 5.6 14.0 10.3 Pscco0.001
25–75% 3.5–11.6 9.5–19.3 7.8–16.8 Pbcco0.001 3.1–8.7 12.4–15.8 8.5–14.9 Pbcco0.001
HLA mismatches
0 165 (15.9) 4 (14.3) 9 (22.5) 0 1 (7.1) 0
1–3 728 (70.3) 23 (82.1) 23 (57.5) Pscc=0.263 46 (25.3) 4 (28.6) 2 (16.7) Pscc=0.3911
4–6 142 (13.7) 1 (3.6) 8 (20.0) Pbcc=0.221 136 (74.7) 9 (64.3) 10 (83.3) Pbcc=0.503
Unknown 8 0 0 0 0 0
ATG or OKT3 as induction or rejection treatment
No 760 (72.9) 21 (75.0) 30 (75.0) Pscc=0.802 44 (24.2) 2 (14.3) 1 (8.3) Pscc=0.400
Yes 283 (27.1) 7 (25.0) 10 (25.0) Pbcc=0.766 138 (75.8) 12 (85.7) 11 (91.7) Pbcc=0.208
Type of maintenance immunosuppression
P+Aza 70 (6.7) 9 (32.1) 5 (12.5) 0 0 0
P+CsA 429 (41.3) 15 (53.6) 23 (57.5) 0 0 0
P+MMF 95 (9.2) 2 (7.1) 2 (5.0) 0 0 0
P+Tac 38 (3.7) 0 0 Pscco0.001 0 0 0 Pscco0.001
P+Aza+CsA 5 (0.5) 0 1 (2.5) Pbcc=0.064 64 (35.2) 14 (100) 5 (41.7) Pbcc=0.218
Table 2 is continued on following page
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origin, HLA matching, maintenance immunosuppressive
regimen, induction and rejection treatments, and level of
immunosuppression on the risk of skin cancer within the
SPKTRs and KTRs (Supplementary Figure S1 and Supplemen-
tary Tables S1a and S1b).
HLA matching and skin cancer
No HLA matching is carried out in SPKTRs. Therefore, the
number of mismatches was much higher among SPKTRs than
in KTRs (Table 1). HLA mismatching, however, was not
significantly associated with SCC or BCC in either the KTRs or
the SPKTRs (Table 2, Supplementary Figure S1f and
Supplementary Tables S1a and S1b).
Immunosuppressive regimens and skin cancer
Immunosuppressive regimens differed strongly between
SPKTRs and KTRs, and changed considerably during the years
(Table 3). SPKTRs always received triple therapy, whereas this
regimen was introduced much later in KTRs (Table 3).
In both KTRs and SPKTRs, immunosuppressive regimens
were associated with the development of SCC but not of BCC
(Table 2, Supplementary Figure S1e and Supplementary
Tables S1a and S1b). For the main analyses, the immuno-
suppressive regimens were categorized into three basic
treatment groups: Aza in any combination, mycophenolate-
mofetil (MMF) in any combination, or CsA or tacrolimus (Tac)
without Aza or MMF.
In the KTR group, immunosuppression with MMF com-
pared with that with Aza was associated with a significantly
decreased risk of SCC (Supplementary Figure S1e, SCC). The
hazard ratio adjusted for age and sex was 0.15 (0.04, 0.59)
(Supplementary Table S1a). Additional adjustments for the
simultaneous use of CsA; for triple versus duo therapy or for
the number of HLA mismatches did not change this hazard
ratio significantly. In the KTR group, immunosuppression
with CsA was also associated with a significantly decreased
risk of SCC compared with that with Aza (Supplementary
Figure S1e, SCC). The hazard ratio adjusted for age and sex
was 0.35 (0.15, 0.84) (Supplementary Table S1a).
In the SPKTR group, immunosuppression with MMF
compared with that with Aza was also associated with a
decreased risk of SCC (Supplementary Figure S1e, SCC). The
hazard ratio could not be calculated, however, because all
SCC cases were immunosuppressed with Aza in any
combination and none with MMF in any combination
(Table 2 and Supplementary Table S1b). SPKTRs who had
maintenance therapy with MMF in any combination seemed
to have an increased risk of BCC compared with patients who
were using maintenance therapy with Aza in any combina-
tion, although statistical significance was not reached, and
this increased risk was not observed in KTRs (Supplementary
Table 2. Continued
KTR SPKTR
Type of skin cancer
No skin cancer
(censored)
SCC as
first event
BCC as
first event P-value
No skin cancer
(censored)
SCC as
first event
BCC as
first event P-value
P+MMF+CsA 275 (26.5) 2 (7.1) 6 (15.0) 81 (44.5) 0 7 (58.3)
P+MMF+Tac 126 (12.1) 0 3 (7.5) 37 (20.3) 0 0
Unknown 5 0 0 0 0 0
Level of immunosuppression2
Low 419 (40.2) 20 (71.4) 25 (62.5) 0 0 0
Moderate 561 (53.8) 7 (25.0) 11 (27.5) Pscc=0.004 44 (24.2) 2 (14.3) 1 (8.3) Pscc=0.627
High 63 (6.0) 1 (3.6) 4 (10.0) Pbcc=0.005 111 (61.0) 9 (64.3) 8 (66.7) Pbcc=0.362
Very high 0 0 0 27 (14.8) 3 (21.4) 3 (25.0)
ATG, anti-thymocyte globulin; Aza, azathioprine; BCC, basal-cell carcinoma; CsA, cyclosporine A; KTR, kidney transplant recipient; MMF,
mycofenolatemofetil; P, prednisolone; SCC, squamous-cell carcinoma; SPKTR, simultaneous pancreas kidney transplant recipient; Tac, tacrolimus.
1For calculation of this P-value the numbers for 0–3 mismatches were combined.
2The level of immunosuppression is defined in the Materials and Methods section.
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Figure 1. Cumulative incidence of skin cancer in 208 SPKTRs compared with
1,111 KTRs. The numbers of SPKTRs and KTRs at risk in relation to years after
transplantation are indicated in Table.
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Figure S1e, BCC). As almost all SPKTRs were immunosup-
pressed with CsA, either in combination with prednisolone
and Aza or with prednisolone and MMF (Table 2), the risk of
SCC associated with the use of CsA could not be calculated in
the SPKTR group.
Induction and rejection treatments and level of
immunosuppression in relation to skin cancer
Among SPKTRs, induction or rejection treatments with anti-
thymocyte globulin (ATG) or muromonab (OKT3) were not
associated with an increased risk of NMSC, SCC, or BCC
(Supplementary Figure S1h–j). The hazard ratios adjusted for
age, sex, and immunosuppressive therapy for induction and
rejection treatments to develop NMSC were 0.91 (0.38, 2.2)
and 1.5 (0.42, 5.4), respectively. For SCC, the adjusted
hazard ratios were 0.92 (0.29, 3.0) and 1.3 (0,15, 10.1),
respectively, and for BCC they were 0.68 (0.18, 2.6) and 2.4
(0.49, 12.1), respectively.
Owing to insufficient numbers of induction treatments
among KTRs in this subgroup, we could only calculate the
hazard ratios for rejection treatments. The adjusted hazard
ratios were 0.75 (0.42, 1.4), 0.63 (0.25, 1.6), and 0.83 (0.38,
1.8) for NMSC, SCC, and BCC, respectively.
As the biological effects of ATG and OKT3 are supposed to
be similar before and after transplantation, induction and
rejection treatments with ATG and/or OKT3 were combined.
Treatment with ATG and/or OKT3 at any time was not
significantly associated with the development of NMSC, SCC,
or BCC in this study (Supplementary Figure S1j and
Supplementary Tables S1a and S1b).
Triple therapy and treatment with ATG and/or OKT3 are
the most important factors determining the level of immuno-
suppression. By combining these treatment modalities, we
estimated a ‘‘general’’ level of immunosuppression. Using
this estimation, the level of immunosuppression was not
consistently associated with NMSC, SCC, or BCC (Supple-
mentary Figure S1k and Supplementary Tables S1a and S1b).
In the SPKTR, we also calculated the median daily doses of
prednisone, Aza, MMF, CsA, and Tac, none of which were
associated with skin cancer (data not shown).
Table 3. Immunosuppressive therapy of 1,111 KTRs and 208 SPKTRs according to time periods of transplantation,
corresponding with major changes in immunosuppressive regimen
KTR SPKTR
Transplantation period 1986–1995 1996–2001 2002–2005 P-value 1986–1995 1996–2001 2002–2005 P-value
No. of patients 530 289 292 72 77 59
SCC total (first event) 34 (25) 3 (2) 1 (1) 16 (13) 2 (1) 0 (0)
BCC total (first event) 33 (28) 10 (8) 5 (4) 10 (5) 7 (7) 0 (0)
ATG or OKT3 as induction or rejection treatment
No 327 (61.7) 223 (77.2) 261 (89.4) Po0.001 11 (15.3) 22 (28.6) 14 (23.7) P=0.148
Yes 203 (38.3) 66 (22.8) 31 (10.6) 61 (84.7) 55 (71.4) 45 (76.3)
Type of maintenance immunosuppression N (%) N (%) N (%) N (%) N (%) N (%)
P+Aza 83 (15.7) 1 (0.3) 0 0 0 0
P+CsA 374 (70.8) 86 (29.9) 7 (2.4) 0 0 0
P+MMF 37 (7.0) 41 (14.2) 21 (7.2) 0 0 0
P+Tac 1 (0.2) 27 (9.4) 10 (3.4) Po0.001 0 0 0 Po0.001
P+Aza+CsA 6 (1.1) 0 0 72 (100) 8 (10.4) 3 (5.1)
P+MMF+CsA 26 (4.9) 99 (34.3) 158 (54.5) 0 69 (89.6) 19 (32.2)
P+MMF+Tac 1 (0.2) 34 (11.8) 94 (32.4) 0 0 37 (62.7)
Unknown 2 1 2 0 0 0
Level of immunosuppression1
Low 307 (57.9) 124 (42.9) 33 (11.3) 0 0 0
Moderate 211 (39.8) 132 (45.7) 236 (80.8) Po0.001 11 (15.3) 22 (28.6) 14 (23.7) P=0.179
High 12 (2.3) 33 (11.4) 23 (6.9) 45 (62.5) 47 (61.0) 36 (61.0)
Very high 0 0 0 16 (22.2) 8 (10.4) 9 (15.3)
ATG, anti-thymocyte globulin; Aza, azathioprine; BCC, basal-cell carcinoma; CsA, cyclosporine A; KTR, kidney transplant recipient; MMF,
mycofenolatemofetil; P, prednisolone; SCC, squamous-cell carcinoma; SPKTR, simultaneous pancreas kidney transplant recipient; Tac, tacrolimus
1The level of immunosuppression is defined in the Materials and Methods section.
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SPKTRs have an increased risk of SCC compared with KTRs,
which can be partly explained by confounding by an
immunosuppressive regimen
Non-stratified Kaplan–Meier analyses and analyses
stratified for potentially confounding factors are shown
in Supplementary Figure S2, and non-adjusted and
adjusted hazard ratios of developing NMSC, SCC, or BCC
in SPKTRs compared with those in KTRs are presented in
Table 4.
The Kaplan–Meier analyses show an increased risk of
SCC in SPKTRs compared with that in KTRs in almost all
strata (Supplementary Figure S2). Supplementary Figure S2d
shows that SPKTRs were much younger at transplantation
than were KTRs. Adjustment for age, therefore, increased
the hazard ratio for the association between transplanted
organ and SCC (Table 4). Supplementary Figure S2f shows
that risk of SCC was much lower in the group of patients
who were immunosuppressed with MMF in any combination.
Adjustment for maintenance immunosuppression decreased
the hazard ratio for the association between transplanted
organ and SCC, which was adjusted for age and sex
from 6.2 (3.0–12.8) to 3.1 (1.3, 7.2), which suggests
a partial confounding by maintenance immunosuppression
(Table 4). Adjustment for other potentially confounding
factors did not reduce the hazard ratios for SCC notably
(Table 4).
The risk of BCC in SPKTR compared with that in KTR was
reduced after adjustment for HLA mismatching and for the
level of immunosuppression, and, when all relevant poten-
tially confounding factors were introduced into the Cox’s
proportional hazard model, the increased risk of BCC largely
disappeared (Table 4).
DISCUSSION
This study showed, after adjustment for age and sex, a
6.2-fold (95% CI: 3.0–12.8) increased risk of SCC in SPKTRs
than in KTRs who were transplanted in the same center
during the same time period. After an additional adjustment
for maintenance immunosuppression, this risk decreased to
3.1 (1.3, 7.2). The risk of BCC was not statistically
significantly increased in SPKTRs after adjustment for
potentially confounding factors.
Maintenance immunosuppressive therapy with MMF in
any combination had led to a significantly decreased risk of
SCC compared with maintenance immunosuppressive ther-
apy with Aza. SPKTRs were more often immunosuppressed
with Aza than were KTRs. Adjustment for this factor, indeed,
reduced the risk of SCC in SPKTRs compared with that in
KTRs, suggesting that the increased risk of SCC in SPKTRs can
be partly explained by confounding by the type of
maintenance immunosuppressive therapy. There remained,
however, a statistically significant threefold increased risk of
SCC in SPKTR, for which we looked for other potential
explanations.
Apart from an obligate history of diabetes in SPKTRs and
differences in maintenance immunosuppression, other differ-
ences discerning SPKTRs from KTRs are more frequent
induction and rejection therapies, and the absence of HLA
matching in SPKTRs. Moreover, these factors could poten-
tially explain the increased risk of SCC in SPKTRs compared
with that in KTRs.
The incidence of NMSC in patients with type I diabetes
has not been systematically studied (Zendehdel et al., 2003;
Swerdlow et al., 2005). Only Zendehdel et al. (2003) showed
a modest, but statistically nonsignificant increase in NMSC,
Table 4. Risk of skin cancer in SPKTRs compared with KTRs with adjustment for potentially confounding factors
using Cox’s proportional hazard analyses
Adjustments
Non-melanocytic
skin cancer SCC as first event BCC as first event
No adjustment 3.0 (1.9, 4.8) 4.2 (2.2, 8.1) 2.5 (1.3, 4.9)
Age 4.0 (2.4, 6.5) 6.3 (3.1, 13.0) 3.1 (1.5, 6.1)
Sex 3.0 (1.9, 4.8) 4.1 (2.1, 8.0) 2.5 (1.3, 4.9)
Age and sex 4.0 (2.4, 6.5) 6.2 (3.0, 12.8) 3.1 (1.5, 6.2)
Age, sex, and country of origin1 3.8 (2.3, 6.2) 5.7 (2.8, 11.8) 3.0 (1.5, 6.0)
Age, sex, and HLA mismatching2 3.3 (1.7, 6.3) 8.3 (3.4, 20.2) 1.7 (0.72, 4.0)
Age, sex, and maintenance immunosuppression3 3.0 (1.7, 5.5) 3.1 (1.3, 7.2) 3.1 (1.4, 6.9)
Age, sex, and ATG or OKT3 as induction or rejection treatment 3.9 (2.3, 6.7) 6.3 (2.9, 13.9) 2.9 (1.4, 6.2)
Age, sex, and level of immunosuppression4 2.4 (1.0, 5.9) 6.5 (1.7, 25.3) 1.3 (0.43, 4.0)
Age, sex, HLA mismatching, and maintenance immunosuppression 2.5 (1.2, 5.1) 3.8 (1.4, 10.2) 1.8 (0.68, 4.5)
ATG, anti-thymocyte globulin; Aza, azathioprine; BCC, basal-cell carcinoma; CsA, cyclosporine A; MMF, mycofenolatemofetil; SCC, squamous-cell
carcinoma.
1The Netherlands and neighbor countries, Mediterranean countries, or Suriname, Africa, or Asia.
2No, 1–3, or 4–6 HLA-A, HLA-B, and HLA-DR mismatches.
3Aza in any combination, MMF in any combination, or CsA or Tac without Aza or MMF.
4Low, moderate, high, or very high immunosuppression as explained in the Materials and Methods section.
www.jidonline.org 2891
HC Wisgerhof et al.
Risk of Skin Cancer in SPKTR and KTR
with a standardized incidence ratio of 1.9 (0.6–4.3) in
patients who had type I diabetes mellitus for more than
15 years. In organ-transplant recipients, diabetes was asso-
ciated with a decreased risk of NMSC (Kasiske et al., 2004;
Otley et al., 2005a). It is therefore not likely that type I diabetes
may explain the increased risk of SCC among SPKTRs.
Induction treatments, impending graft rejection, and
subsequent rejection therapies were not associated with
SCC or BCC in this study, although the follow-up periods
may still have been too short to detect such an effect.
Adjustment for induction and rejection treatments did not
change the increased risk of SCC in SPKTRs, excluding also
these factors as major causes for the increased risk of SCC in
SPKTRs.
Although HLA matching has been reported to be
associated with skin cancer in an earlier study (Bouwes
Bavinck et al., 1991), we were not able to confirm this
association in this study. Adjustment for HLA matching did
not influence the risk of SCC among SPKTRs; hence, poor
HLA matching could not explain the increased risk of SCC in
SPKTRs. The risk of BCC in SPKTRs, compared with that in
KTRs, however, decreased after adjustment for HLA match-
ing, suggesting that poor HLA matching could partly explain
the increased risk of BCC in SPKTRs.
Differences in the number of induction and graft rejection
treatments, as well as HLA matching, did not provide a good
explanation for the increased risk of SCC in SPKTRs compared
with KTRs. However, other differences between the two
groups might be responsible for this outcome. Compared with
KTRs, in SPKTRs, a second transplanted organ is present.
Induction of tolerance is an important goal of clinical organ
transplantation (Kean et al., 2006; Kawai et al., 2008), and
may also have undesirable side effects, such as an increased
risk of skin cancer. We speculate that transplanted pancreas
may induce tolerance against an additional set of allo-
peptides in the HLA antigens of the donor. Although we are
not aware of any published examples of this mechanism in
humans who have received a double set of other organs (for
example, heart and lung), a reduced rejection rate of the
transplanted heart has been described in rats who received a
heart in combination with a lung or spleen (Westra et al.,
1991). An increased cross-reactive tolerance against SCC-
associated antigens in the host could then lead to an increased
risk of SCC in SPKTRs, which could potentially affect SCC
more severely than BCC, as SCCs are more antigenic cancers
than are BCCs (Muchemwa et al., 2006). Future studies should
point out whether this hypothesis is true.
The overall SCC:BCC ratio in this study was 0.79, which is
lower than the ratio of 1.6 in our earlier study (Hartevelt
et al., 1990). After the introduction of maintenance therapy
with MMF instead of Aza, a decreased risk of SCC was
observed, while the risk of BCC was not decreased or even
possibly increased. Therefore, this change in maintenance
therapy may explain, at least partly, the lower SCC:BCC ratio.
The length of the follow-up period may form another
explanation, as BCCs tend to occur earlier after transplanta-
tion than SCCs, but after a latent period, the cumulative
incidence of SCC increases more rapidly than that of BCC.
The high collinearity of the immunosuppressive regimen,
as well as HLA matching with the type of organ transplanted
and the relatively limited numbers of first events, is the most
important limitation of this study. The high collinearity could
easily result in overfitting in the model so that the association
between transplanted organ and skin cancer could disappear.
The limited numbers of first events provided insufficient
power, limiting the number of reliable stratified analyses.
As the risk of developing skin cancers in transplant recipients
is highly increased, excessive exposure to sunlight should be
avoided and use of daily sunscreen should be advised. In
addition, strict control in an outpatient clinic is important for
diagnosing skin cancers at an early stage, facilitating the best
treatment and preventing further complications.
MATERIALS AND METHODS
Patients
All 208 patients who received an SPKT at the LUMC between March
1986 and January 2006 were included in this cohort study and were
compared with all 1,111 KTRs transplanted in the LUMC during the
same time period. The study adhered to the Declaration of Helsinki
Principles and the medical ethical committee of the LUMC had
approved the study design.
Collection of data
Data recorded for all SPKTRs and KTRs included the country of
origin, the dates of transplantations, age at transplantation, sex, and
the dates of death or last follow-up visit. During the first post-
transplant years, all patients with functional grafts were seen in the
Department of Nephrology, LUMC. Only 88 (6.7%) patients (4
SPKTRs and 84 KTRs) were later followed up in other centers in the
Netherlands. In total, 11 (0.8%) patients (1 SPKTR and 10 KTRs) were
lost to follow-up, mainly because they moved to another country.
The country of origin was used as a rough estimation of the skin
type. Altogether, 1,176 patients originated from the Netherlands or
countries with a comparable distribution of skin type. A total of 61
patients originated from Mediterranean countries (1 from France, 2
from Israel, 2 from Iran, 2 from Iraq, 1 from Italy, 20 from Morocco,
1 from Spain, 1 from Tunisia, 26 from Turkey, and 5 from (former)
Yugoslavia) and 82 from countries with a dark skin type (29 from
Africa, 9 from Indonesia, 5 from other parts of Asia, and 39 from
Suriname or Dutch Antilles).
Patients with skin problems were also seen and followed up at the
Department of Dermatology, LUMC. Skin biopsies were routinely
carried out when skin cancers were suspected. Skin cancer data
were collected from the computerized oncological registry of the
LUMC, the database from the department of Pathology, and from the
national histological database (PALGRA). Follow-up data were
collected until June 2007.
Of 1,111 KTRs, 9 recipients (5 with malignant melanoma, 2 with
Kaposi’s sarcoma, 1 with sweat gland carcinoma and 1 with
fibrosarcoma) were present, but no SPKTR developed skin cancers
other than NMSC after transplantation. These skin cancers are not
further discussed.
Immunosuppressive regimens and HLA matching
Information about the initial and maintenance immunosuppressive
therapy of all patients was obtained from the Eurotransplant
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database. Type of induction therapy and the number and type of
rejection treatments were collected from the flow sheets in the
medical charts of the department of nephrology.
For SPKTRs, the initial and maintenance immunosuppressive
therapy between 1986 and 1995 consisted of prednisolone
(7.5–10mgday1), Aza (50–100mgday1), and CsA (200–300mg
day1). Between 1996 and 2001, almost all new patients
were treated with prednisolone (7.5–10mgday1), MMF
(2,000mg day1), and CsA (200–300mgday1). Since 2002, the
immunosuppressive treatment of all new patients has consisted of
prednisolone (7.5–10mgday1), MMF (1,000–1,500mgday1), and
Tac (6–10mgday1). In most SPKTRs, maintenance therapy was
identical to initial treatment.
For KTRs, immunosuppressive treatment initially consisted of duo
therapy with prednisolone and Aza, but shortly after 1986, all new
KTRs were immunosuppressed with prednisolone and CsA. After
1996, triple therapy also became the treatment of choice among
KTRs, whereby, initially, most new KTRs were treated with
prednisolone, MMF, and CsA, and later, most new KTRs were
treated with prednisolone, MMF, and Tac. The target blood levels for
immunosuppressive drugs were the same for the KTR group as for the
SPKTR group. Of 1,111 KTRs, in 667 (60%) recipients, maintenance
therapy was identical to initial therapy. Starting in 1996, in
39 patients, CsA was switched to MMF, and in 23 patients, MMF
was added to prednisolone and CsA. Details of maintenance
immunosuppressive regimens, categorized according to three time
periods of transplantation, for all SPKTRs and KTRs are provided in
Table 3.
A total of 112 of the 208 SPKTRs received induction therapy to
prevent a rejection of the graft by administration of muromonab
(OKT3) (24 patients), ATG (63 patients), daclizumab (23 patients), or
basiliximab (2 patients). With the exception of some rare patients,
induction treatments with ATG and/or OKT3 were not given to KTRs
who were transplanted in the LUMC. Starting in 2000, however,
induction treatment with basiliximab became common practice
among KTRs.
SPKTRs and KTRs, in whom acute graft rejections were observed,
were almost always initially treated with methylprednisolone.
When this therapy was not sufficient to prevent further rejection,
a second and third rejection treatment with ATG and once
more with methylprednisolone, respectively, was given. In excep-
tional cases, OKT3 was given when a fourth rejection treatment was
needed.
To estimate the level of immunosuppression, we categorized the
patients into four groups. Triple therapy instead of duo therapy and
therapy with ATG or OKT3 as induction or rejection therapy were
considered as factors increasing the level of immunosuppression.
‘‘Low’’ level of immunosuppression was defined as duo therapy
without induction or rejection therapy with ATG or OKT3;
‘‘moderate’’ level of immunosuppression was defined as (a) triple
therapy without induction or rejection therapy or (b) duo therapy
with induction or rejection therapy with ATG or OKT3; ‘‘high’’ level
of immunosuppression was defined as (a) triple therapy with
induction or rejection therapy with ATG or OKT3, or (b) duo
therapy with both induction and rejection therapy with ATG or
OKT3; and a ‘‘very high’’ level of immunosuppression was defined
as triple therapy and both induction and rejection therapy with ATG
or OKT3.
The degree of HLA mismatching for HLA-A, HLA-B, and HLA-DR
antigens was assessed by counting the antigens present in the donor
but absent in the recipient.
Statistical analyses
For analyses of SCCs and BCCs together, we used the term NMSC.
We used all recipients with SCC (with or without BCC) and all
recipients with BCC (with or without SCC) to calculate the
cumulative incidence of SCCs and BCCs (Kaplan–Meier analyses).
For all other analyses involving SCC and BCC, we used patients with
SCCs or BCCs as first event to avoid patients with both SCCs and
BCCs being used twice in our analyses. Performing our analyses on
all recipients with SCC (with or without BCC) or on all recipients
with BCC (with or without SCC) did not lead to significantly different
outcomes.
The initial and maintenance immunosuppressive therapies were
categorized into three basic treatment groups: duo or triple therapy
with Aza in any combination, duo or triple therapy with MMF in any
combination, and duo therapy without Aza or MMF (that is, a
combination of prednisolone with CsA or prednisolone with Tac). If no
data were available for maintenance immunosuppressive therapy, the
data of the initial immunosuppressive therapy were used. For all our
analyses with immunosuppressive therapy, we used the subcategor-
ization of maintenance therapy because the patients were, generally,
exposed to this regimen for the most prolonged period of time.
Because ATG and OKT3 exert by far the highest immunosup-
pressive effect, induction and rejection treatments were dichoto-
mized into those with and without ATG and/or OKT3. Because the
biological effects of ATG and OKT3 are supposed to be similar
before and after transplantation, exposures to ATG and/or OKT3 as
induction or rejection treatment were also combined for our
analyses.
Differences between patients with and without skin cancer were
analyzed by the w2 (categorical variables) and Student’s t-tests
(continuous variables). Kaplan–Meier survival analyses were used to
estimate the cumulative incidence of skin cancer after transplanta-
tion. Cox’s proportional hazard analyses were used to calculate
hazard ratios for the development of skin cancer and to adjust for
potentially confounding factors. As opening dates for both analyses,
we used the date of first transplantation; as closing dates, we used
the date of diagnosis of the first SCC or BCC, the date of the patient’s
death, the date of last follow-up, the date that they were lost to
follow-up, or, if the patients were still seen in an outpatient clinic,
we used the date of the end of the study (1 June 2007). The patients
were not censored from analyses at graft failure. Censoring patients
from analyses because of failure of the first graft did not lead to
significantly different outcomes. We assessed proportionality of
hazards by plotting Schoenfeld residuals for relevant covariates and
by introducing interactions of relevant covariates with time in the
Cox’s proportional hazard model.
For all statistical analyses, we used SPSS version 14.0.1 (SPSS,
Chicago, IL).
Analytical strategy to test for confounding
First, potential risk factors for NMSC, SCC, and BCC were identified
with Kaplan–Meier analyses stratified for SPKTR and KTR (Supple-
mentary Figure S1) and in multivariable Cox’s proportional hazard
models (Supplementary Tables S1a and S1b). Subsequently, a
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possible confounding of the association between transplanted organ
and skin cancer was tested with Kaplan–Meier analyses stratified for
the potential risk factors of interest (Supplementary Figure S2) and in
multivariable Cox’s proportional hazard models (Table 4). The Cox’s
proportional hazard analyses were initially carried out without any
adjustment and subsequently with adjustments for age and sex. The
hazard ratios adjusted for age and sex were further adjusted for other
potentially confounding factors (Table 4). Age and sex, HLA
matching, and maintenance immunosuppression had the most
important modulating effect on the association between transplanted
organ and skin cancer, and these factors were, therefore, included in
the final model. Maintenance immunosuppression, use of ATG or
OKT3, and level of immunosuppression could not be included in the
model together because of collinearity and overfitting.
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